press release Heajin Kim 4/29/25 press release Heajin Kim 4/29/25 Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting Read More press release Heajin Kim 3/9/25 press release Heajin Kim 3/9/25 Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference Read More press release Heajin Kim 3/6/25 press release Heajin Kim 3/6/25 Luxa's stem cell therapy for dry AMD shows early promise Read More press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More press release Heajin Kim 10/1/24 press release Heajin Kim 10/1/24 Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer Read More Older Posts
press release Heajin Kim 4/29/25 press release Heajin Kim 4/29/25 Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting Read More
press release Heajin Kim 3/9/25 press release Heajin Kim 3/9/25 Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference Read More
press release Heajin Kim 3/6/25 press release Heajin Kim 3/6/25 Luxa's stem cell therapy for dry AMD shows early promise Read More
press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More
press release Heajin Kim 10/1/24 press release Heajin Kim 10/1/24 Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer Read More
